Patient-reported outcomes (PROs) are increasingly being used to compare the quality of outcomes between different healthcare providers (medical practices, hospitals, rehabilitation facilities). However, such comparisons can only be fair if differences in the case-mix between different types of provider are taken into account. This can be achieved with adequate statistical case-mix adjustment (CMA). To date, there is a lack of overview studies on current CMA methods for PROs. The aim of this study was to investigate which approaches are currently used to report and examine PROs for case-mix-adjusted comparison between providers. A systematic MEDLINE literature search was conducted (February 2021). The results were examined by two reviewers. Articles were included if they compared (a) different healthcare providers using (b) case-mix-adjusted (c) patient-reported outcomes (all AND conditions). From 640 hits obtained, 11 articles were included in the analysis. A wide variety of patient characteristics were used as adjustors, and baseline PRO scores and basic sociodemographic and clinical information were included in all models. Overall, the adjustment models used vary considerably. This evaluation is an initial attempt to systematically investigate different CMA approaches for PROs. As a standardized approach has not yet been established, we suggest creating a consensus-based methodological guideline for case-mix adjustment of PROs.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8392243 | PMC |
http://dx.doi.org/10.3390/cancers13163964 | DOI Listing |
BMC Public Health
January 2025
School of Public Health, Southeast University, Nanjing. 87 Dingjiaqiao Road, Nanjing, China.
Background: Triglyceride-glucose (TyG) index was regarded as a cost-efficient and reliable clinical surrogate marker for insulin resistance (IR), which was significantly correlated with cardiovascular disease (CVD). However, the TyG index and incident CVD in non-diabetic hypertension patients remains uncertain. The aim of study was to explore the impact of TyG index level and variability on risk of CVD among non-diabetic hypertension patients.
View Article and Find Full Text PDFEur J Clin Nutr
January 2025
Department of Nutrition and Dietetics, School of Health Sciences and Education, Harokopio University of Athens, Kallithea, Athens, Attica, Greece.
Background: The long-term effects of breakfast on childhood z-BMI remain inconclusive.
Objective: To prospectively assess the impact of stable and altered breakfast consumption habits on z-BMI change over two years, in school-aged children across six European countries.
Methods: Data of 6,528 children (8.
J Prev Alzheimers Dis
February 2025
Department of Biostatistics, Boston University School of Public Health, Boston, MA, USA; The Framingham Study, Framingham, MA, USA; Department of Neurology, Boston University School of Medicine, Boston, MA, USA.
Background: Ultra-processed food consumption is emerging as a risk factor for various cardiometabolic diseases, however its association with dementia and Alzheimer's disease has rarely been explored.
Objectives: We sought to examine whether ultra-processed food consumption is associated with risk of all-cause dementia and Alzheimer's disease among middle-age and older adults.
Design: A prospective cohort study.
BMJ Open Gastroenterol
January 2025
Institute of Applied Health Research, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK.
Objective: To develop and validate a prognostic model for risk-stratified monitoring of 5-aminosalicylate nephrotoxicity.
Methods: This UK retrospective cohort study used data from the Clinical Practice Research Datalink Aurum and Gold for model development and validation respectively. It included adults newly diagnosed with inflammatory bowel disease and established on 5-aminosalicylic acid (5-ASA) treatment between 1 January 2007 and 31 December 2019.
Travel Med Infect Dis
January 2025
Centre National de Référence du Paludisme, Paris, France; Centre de Recherche en Epidémiologie et Santé des Populations (CESP), INSERM U1018, Paris, France; Université Paris-Saclay, Service des Maladies infectieuses et tropicales, APHP, Hôpital Bicêtre, Le Kremlin-Bicêtre, France; Société Française de Médecine des Voyages.
Background: Post-Artesunate delayed hemolysis (PADH) occurs in approximately 15% of treated patients 2 to 3 weeks after artesunate administration. Identifying risk markers for PADH would help predict which patients are at higher risk.
Methods: In this prospective national cohort study conducted in a non-malaria endemic area from 2011 to 2016, a Cox proportional hazards model was used to assess the association between clinical and biological data available at Day 0 and the occurrence of PADH within 30 days of artesunate administration.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!